维持性透析患者中乙型肝炎疫苗(Engerix-B®)与乙型肝炎疫苗-CpG(Heplisav-B®)血清保护率的真实世界比较
该回顾性队列分析纳入2019年1月至2020年12月完成乙型肝炎疫苗或乙型肝炎疫苗-CpG接种的透析患者,比较血清保护率。系列1中乙型肝炎疫苗组血清保护率显著高于乙型肝炎疫苗-CpG组(62.9% vs 50.1%,P<0.0001),系列2和加强针组两疫苗血清保护率相似;初始使用乙型肝炎疫苗-CpG并必要时用于系列2可更早达到更高血清保护率。
要点
- 系列1中乙型肝炎疫苗组血清保护率62.9%,显著高于乙型肝炎疫苗-CpG组的50.1%(P<0.0001)。
- 系列2和加强针组中,两种疫苗的血清保护率相似。
- 接受最多四剂乙型肝炎疫苗-CpG的患者血清保护率82.0%,高于四剂乙型肝炎疫苗的62.9%(P<0.0001)。
核心结论
- 在未接种过乙型肝炎疫苗的透析患者中,按推荐接种四剂乙型肝炎疫苗的血清保护率高于按推荐接种两剂乙型肝炎疫苗-CpG。
- 若初始使用乙型肝炎疫苗-CpG并在需要时用于系列2,血清保护率更高且达到更早。
- 乙型肝炎疫苗-CpG的最佳给药方案值得进一步研究。
研究设计与样本
- 回顾性队列分析,纳入2019年1月至2020年12月完成乙型肝炎疫苗或乙型肝炎疫苗-CpG接种的透析患者。
- 未接种过疫苗的患者接受乙型肝炎疫苗或乙型肝炎疫苗-CpG系列(系列1),无应答者接受重复系列(系列2),加强方案为任一疫苗一剂。
- 主要结局为系列1和系列2末次乙型肝炎疫苗接种后至少60天达到血清保护(anti-HBs >10 mIU/mL),以及加强针后至少3周达到血清保护。
主要发现
- 系列1(n=3509)中,乙型肝炎疫苗组血清保护率为62.9%,乙型肝炎疫苗-CpG组为50.1%,差异显著(P<0.0001)。
- 系列2(n=1040)和加强针(n=2028)中,两种疫苗的血清保护率相似。
- 接受最多四剂乙型肝炎疫苗-CpG的患者血清保护率为82.0%,接受四剂乙型肝炎疫苗的患者为62.9%(P<0.0001)。
关键数值与推荐
- 血清保护定义为anti-HBs >10 mIU/mL,于系列1和系列2末次乙型肝炎疫苗接种后至少60天评估,加强针后至少3周评估。
- 系列1中乙型肝炎疫苗组血清保护率62.9%,乙型肝炎疫苗-CpG组50.1%(P<0.0001)。
- 接受最多四剂乙型肝炎疫苗-CpG组血清保护率82.0%,四剂乙型肝炎疫苗组62.9%(P<0.0001)。
临床怎么用
- 在未接种过乙型肝炎疫苗的维持性透析患者中,按推荐接种四剂乙型肝炎疫苗的血清保护率高于按推荐接种两剂乙型肝炎疫苗-CpG。
- 若初始使用乙型肝炎疫苗-CpG并在需要时用于系列2,血清保护率更高且达到更早。
- 乙型肝炎疫苗-CpG的最佳给药方案值得进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccination against hepatitis B virus (HBV) is recommended for dialysis patients. Two reports comparing seroprotection (SP) rates following HepB and HepB-CpG in vaccine-naïve patients with chronic kidney disease enrolled few dialysis patients (n = 122 combined). SP rates in a subset of dialysis patients were not reported or not powered to detect statistically significant differences. SP rates in those requiring additional vaccine series or booster doses are not known. METHODS: A retrospective cohort analysis including dialysis patients completing HepB or HepB-CpG vaccination between January 2019 and December 2020. Vaccine-naïve patients received a series of HepB or HepB-CpG (Series 1). A repeat series was given to nonresponders (Series 2). A booster regimen consists of one dose of either vaccine. Primary outcome was achieving SP (anti-HBs >10 mIU/mL) at least 60 days after the last HBV vaccine dose for Series 1 and Series 2, and achieving SP at least 3 weeks post-booster. RESULTS: For Series 1 (n = 3509), SP after HepB vaccination was significantly higher (62.9% versus 50.1% for HepB-CpG; P < 0.0001). Series 2 (n = 1040) and booster (n = 2028) SP rates were similar between vaccines. Patients that received up to four HepB-CpG doses had higher SP rates compared with four doses of HepB (82.0% versus 62.9%, respectively; P < 0.0001). CONCLUSIONS: SP rates in hepatitis B vaccine-naïve dialysis patients administered a recommended four doses of HepB were higher than those recommended two doses of HepB-CpG. SP rates were higher and achieved sooner if HepB-CpG was utilized initially and, if needed, for Series 2. Optimal HepB-CpG dosing deserves further study.
引用
- Manley HJ, Aweh G, Frament J, et al. A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis. Nephrol Dial Transplant. 2023. PMID: 35150277. doi:10.1093/ndt/gfac039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。